文献速递免疫规划

先前接种三价铝佐剂减量灭活脊髓灰质炎疫苗Picovax®的4岁儿童保护性抗脊髓灰质炎病毒抗体水平的持续性

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.
PubMed 文献 · Vaccine · 2022-09-03

本研究为两项先前试验的延伸,评估先前以减量铝佐剂灭活脊髓灰质炎疫苗(IPV-Al,Picovax®)进行基础免疫和加强免疫的4岁儿童(末次接种后2.5年)保护性抗体(滴度≥8)的持续性,并确定额外一剂IPV-Al的加强应答和安全性。结果显示,入组时1、2、3型脊灰病毒血清保护率分别为89.2%、100%和91.1%;额外接种后除1名受试者外均达到保护阈值(1型99.4%,2型和3型100%),并诱导1、2、3型滴度分别升高26.3、13.9和30.9倍的稳健加强应答;疫苗耐受良好,仅报告轻微和短暂的不良事件。

要点

  • 4岁时(末次接种后2.5年)1、2、3型脊灰病毒血清保护率分别为89.2%、100%和91.1%。
  • 额外接种一剂IPV-Al后,1型血清保护率99.4%,2型和3型均为100%。
  • 额外剂量诱导1、2、3型脊灰病毒抗体滴度分别升高26.3、13.9和30.9倍。

核心结论

  • 以铝佐剂减量IPV基础免疫可诱导持久的免疫记忆,表现为末次接种2.5年后再次暴露抗原时出现稳健的回忆应答。
  • IPV-Al是增加全球灭活脊髓灰质炎疫苗可及性的有效且安全的补充。

研究设计与样本

  • 本研究为两项先前试验(基础免疫试验和加强免疫试验)的延伸试验。
  • 邀请参与两项先前试验的儿童在4岁时(加强剂后2.5年)接种一剂IPV-Al,并采集接种前后血样检测抗体滴度。
  • 记录全身不良事件和局部反应原性。
  • 临床试验注册号:NCT04448132。

主要发现

  • 入组时针对脊髓灰质炎病毒1、2、3型的血清保护率分别为89.2%、100%和91.1%。
  • 额外接种IPV-Al后,除1名受试者外,所有受试者的1、2、3型脊灰病毒抗体水平均升至血清保护阈值以上,即1型99.4%,2型和3型100%。
  • 额外剂量诱导1、2、3型脊灰病毒滴度分别升高26.3、13.9和30.9倍。
  • 疫苗耐受良好,仅报告轻微和短暂的不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To meet the demand for effective and affordable inactivated polio vaccines (IPVs), a reduced dose, aluminium hydroxide (Al(OH)3)-adjuvanted IPV vaccine was developed (IPV-Al, Picovax®) and evaluated in clinical trials. The present trial is an extension of two previous trials (a primary and a booster trial). The aim was to evaluate the persistence of seroprotective antibodies (poliovirus type-specific antibody titre ≥ 8) in 4-year-old children who previously received IPV-Al as primary and booster vaccine doses and to determine the potential booster response and safety profile of an additional dose of IPV-Al. METHODS: Children participating in the two previous trials were invited to receive one additional dose of IPV-Al at 4 years of age (2.5 years after the booster dose) and to have their blood samples collected to measure the pre- and post-vaccination antibody titres. Systemic adverse events (AEs) and local reactogenicity were recorded. RESULTS: At study entry, the seroprotection rates were 89.2%, 100% and 91.1% against poliovirus type 1, 2 and 3, respectively. The additional vaccination with IPV-Al boosted the level of poliovirus type 1, 2 and 3 antibodies to above the seroprotection threshold for all but one subject, i.e., 99.4% for type 1 and 100% for types 2 and 3. The additional dose induced a robust booster response of a 26.3-, 13.9- and 30.9-fold increase in titre for poliovirus types 1, 2 and 3, respectively. The vaccine was well tolerated, with only mild and transient AEs reported. CONCLUSIONS: The present trial demonstrated that the primary vaccination with an aluminium-adjuvanted reduced dose IPV induced a persistent immune memory as evidenced by the robust anamnestic response when the subjects were re-exposed to the antigen 2.5 years after the last dose. Thus, the IPV-Al is an efficient and safe addition to increase the availability of inactivated polio vaccines globally. (ClinicalTrials.gov reg no. NCT04448132).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sáez-Llorens X, Chan M, DeAntonio R, et al. Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine. Vaccine. 2022. PMID: 36064670. doi:10.1016/j.vaccine.2022.06.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。